Shanghai Kongshanci Technology has recently secured its Series A financing round, with the raised capital earmarked for product innovation, medical device registration, and global market penetration. The company has pioneered a technological framework centered around a 'whole-brain functional connectivity computational engine, robotic navigation, and multimodal closed-loop modulation.' This framework leverages three key technology pipelines: Transcranial Magnetic Stimulation (TMS), Transcranial Focused Ultrasound (tFUS), and Temporal Interference (TI). Embracing a dual-track strategy that blends 'clinical-grade medical applications with consumer-friendly products,' the company aspires to deliver tailored and effective treatment options for individuals grappling with mental and cognitive disorders, all through the lens of precise brain-computer interaction technology. The company's core team is distinguished by its cross-disciplinary expertise and end-to-end capabilities. It has forged research and clinical partnerships with several prestigious overseas universities and leading medical institutions, with concurrent plans to seek both FDA and CE certifications.